A Scientific Overview of the Pharmacological and Non-Pharmacological Treatment Strategies for Parkinson’s Disease


Program Dates: November 6, 2019 – November 5, 2020
Credits: 1.0 AMA PRA Category 1 Credit™


A Scientific Overview of the Pharmacological and Non-Pharmacological Treatment Strategies for Parkinson’s Disease

Program Overview

This continuing medical education program will highlight recent advances in the treatment and management of patients with Parkinson’s disease (PD), including data presented at the International Congress of Parkinson’s Disease and Movement Disorders (MDS) 2019 in Nice, France.  The three expert faculty will review the pathophysiology of Parkinson’s disease, as well as best practices for early detection and diagnosis of PD in practice.  The faculty will analyze current trial data for both pharmacologic and non-pharmacologic therapies in PD and debate the clinical relevance in an interactive panel format. Strategies for improving patient outcomes and quality of life will be reviewed, considering the optimal role of caregivers in improving adherence to therapy. Upon completion of this programs, learners will be increasingly confident in their ability to treat and manage their patients with Parkinson’s disease.

Target Audience

Neurologists, movement specialists, primary care physicians, internists and other healthcare providers involved in the management of patients with Parkinson’s disease

Agenda

  1. The Pathophysiology of Parkinson’s Disease: The Knowledge of Recognizing and Managing all Stages of Disease
  2. A Scientific Overview of Pharmacological and Non-Pharmacologic al Therapies for the Treatment of Parkinson’s Disease
  3. The Application of Evidence Based Data into Treatment Strategies to Delay Disease Progression in Patients with Parkinson’s Disease

Learning Objectives

  1. Review the pathophysiology of Parkinson’s disease to better recognize and treat all stages of disease.
  2. Analyze the current trial data for pharmacologic and non-pharmacologic therapies for the treatment of Parkinson’s disease.
  3. Apply the most recent evidence-based data into treatment strategies to delay disease progression in patients with Parkinson’s disease.

Faculty

 

Daniel Kremens, MD, JD (Course Chair)
Associate Professor of Neurology
Sidney Kimmel Medical College at Thomas Jefferson University
Co-Director of the Parkinson’s Disease and Movement Disorders Division
Sidney Kimmel Medical College at Thomas Jefferson University
Philadelphia, PA

Stuart Isaacson, MD
Parkinson’s Disease and Movement Disorders Center of Boca Raton
Associate Professor of Neurology
FIU Herbert Wertheim College of Medicine
Boca Raton, FL

 

Rajesh Pahwa, MD
Professor, Movement Disorders Division Chief
University of Kansas Medical Center
Kansas City, KS

 

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Faculty Relationship Identified With:
Daniel Kremens, MD, JD Consultant/Advisor: AbbVie Inc.; ACADIA Pharmaceuticals; Acorda Therapeutics; Adamas Pharmaceuticals; Allergan plc.; Cynapsus Therapeutics; GE Healthcare; Impax Pharma; Kyowa Kirin Pharmaceutical Development, Inc.; Lundbeck; Merz Pharmaceuticals; Neurocrine Biosciences; St. Jude Medical; UCB Pharma, Inc.; US WorldMeds, LLC; Teva Pharmaceuticals USA; Sunovion Pharmaceuticals Inc.

Grant/Research Support: Acorda Therapeutics; Enterin Inc.

Speakers Bureau: Acadia Pharmaceuticals; Acorda Therapeutics; Adamas Pharmacueticals; Impax Laboratories, LLC; Lundbeck; Teva Pharmaceuticals Inc.; UCB Pharma, Inc.; US World Meds

Stuart Isaacson, MD, FAAN

 

Consultant/Advisor: AbbVie Inc.; Acadia Pharmaceuticals Inc.; Acorda Therapeutics, Inc.; Adamas Pharmaceuticals; Addex Therapeutics; Affiris; Alexva Pharmaceuticals; Allergan plc; Amarantus BioScience; Amneal Pharmaceuticals; Axovant Gene Therapies; BenevolentAL; Biogen Inc.; Britannia Pharmaceuticals Ltd.; Cadent Therapeutics; Cala Health; Cerecor Inc.; Cipla Limited; Eli Lilly and Company; Enterin Inc.; GE Healthcare; Global Kinetics; Impax Laboratories, LLC; Impel NeuroPharma; Intec Pharma; Ipsen Biopharmaceuticals; Jazz Pharmaceuticals; Kyowa Kirin Pharmaceutical Development, Inc.; Lundbeck; Merz Pharma; Michael J. Fox Foundation; Mitsubishi Tanabe; Neuralym; Neurocrine Biosciences; Neuroderm Ltd.; Parkinson Study Group; Pharma2B; Prilenia Therapeitics; Promentis Pharmaceuticals, Inc.; Revance Therapeutics Inc.; Roche Pharma; Sanofi US; Sunovion Pharmaceuticals Inc.; Sun Pharma; Teva Pharmaceuticals, Ltd.; Theravance Biopharma, Inc.; UCB, Inc.; US World Meds; Zambon Company S.P.A.

Grant/Research Support: Abbvie Inc.; Acadia Pharmaceuticals Inc.; Acorda Therapeutics; Adamas Pharmaceuticals, Inc.; Addex Therapeutics; Allergan, Inc.; Amarantus Bioscience Holdings, Inc.; Axovant Sciences; BenevolentAI; Biogen; Britannia Pharmaceuticals; Cerecor, Inc.; Enterin Inc.; GE Healthcare; Global Kinetics Corporation Ltd.; IMPAX Laboratories, Inc.; Intec Pharma, Ltd.; Ipsen; Jazz Pharmaceuticals, Inc.; Kyowa Pharmaceutical, Inc.; Lilly; Lundbeck, Inc.; Neurocrine Biosciences, Inc.; NeuroDerm; PharmaTwoB; Roche; Sanofi; Sunovion Pharmaceuticals Inc.; Teva Pharmaceuticals USA; Theravance, Inc.; UCB Pharma, Inc.; US WorldMeds, LLC; Zambon Company S.P.A.

Speakers Bureau: Abbvie Inc.; ACADIA Pharmaceuticals Inc.; Acorda Therapeutics; Adamas Pharmaceuticals, Inc.; Addex Therapeutics; Allergan, Inc.; Amarantus Bioscience Holdings, Inc.; Axovant Sciences; BenevolentAI; Biogen; Britannia Pharmaceuticals; Cerecor, Inc.; Enterin Inc.; GE Healthcare; Global Kinetics Corporation Ltd.; IMPAX Laboratories, Inc.; Intec Pharma, Ltd.; Ipsen; Jazz Pharmaceuticals, Inc.; Kyowa Pharmaceutical, Inc.; Lilly; Lundbeck, Inc.; Neurocrine Biosciences, Inc.; NeuroDerm; PharmaTwoB; Roche; Sanofi; Sunovion Pharmaceuticals Inc.; Teva Pharmaceuticals USA; Theravance, Inc.; UCB Pharma, Inc.; US WorldMeds, LLC; Zambon Company S.P.A.

Rajesh Pahwa, MD

 

Consultant/Advisor: Abbott; AbbVie Inc.; ACADIA Pharmaceuticals Inc.; Acorda Therapeutics Inc.; Adamas Pharmaceuticals; CALA Health; Global Kinetics; Lundbeck; Neurocrine BioScience, PhotoPharmics, Inc.; Prilenia Therapeutics; Sunovion Pharmaceuticals Inc.; Teva Neuroscience; US World Meds

Grant/Research Support: Abbott, AbbVie Inc.; Acorda Therapeutics Inc.; Biogen, Inc.;  Boston Scientific; CALA Health; Cavion; Cynapsus Therapeutics; Intec Pharma; Jazz Pharmaceuticals; Kyowa Group; Eli Lilly and Company; NIH/NINDS; NPF; PSG; Roche Pharma; Sunovion Pharmaceuticals, Inc.; Theranexus; Theravance Biopharma, Inc.; US WorldMeds; Voyager Therapeutics

 

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), theAccreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statements

AcademicCME designates this live material for a maximum of 1.0 AMA PRA Category 1 Credit TM. Participants should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

This activity has been supported by independent educational grants from Acorda Therapeutics and Biogen

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME, Acorda Therapeutics and Biogen do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions andcomplete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
    • CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
    • CME and CNE credit will be issued appropriate certificate of completion.
    • Others may request a “certificate of completion”.
  1. Learners should claim only the credit commensurate with the extent of their participation in the activity.

 

CE Inquiries/Special Needs

For all CE inquiries or special needs, please contact [email protected].

BUTTON

Provided by: AcademicCME-web